Total Payments
$44,626
2024 Payments
$375.00
Companies
3
Transactions
24
Medicare Patients
504
Medicare Billing
$61,144
Payment Breakdown by Category
Research$43,775 (98.1%)
Consulting$500.00 (1.1%)
Travel$350.82 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $43,775 | 21 | 98.1% |
| Consulting Fee | $500.00 | 1 | 1.1% |
| Travel and Lodging | $350.82 | 2 | 0.8% |
Payments by Type
Research
$43,775
21 transactions
General
$850.82
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $43,400 | 19 | $0 (2022) |
| SANOFI US SERVICES INC. | $875.00 | 3 | $0 (2024) |
| Stryker Corporation | $350.82 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $375.00 | 2 | SANOFI US SERVICES INC. ($375.00) |
| 2023 | $500.00 | 1 | SANOFI US SERVICES INC. ($500.00) |
| 2022 | $7,300 | 5 | Regeneron Pharmaceuticals, Inc. ($7,300) |
| 2021 | $34,851 | 15 | Regeneron Pharmaceuticals, Inc. ($34,500) |
| 2020 | $1,600 | 1 | Regeneron Pharmaceuticals, Inc. ($1,600) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/21/2024 | SANOFI US SERVICES INC. | DUPIXENT (Biological) | — | Cash or cash equivalent | $250.00 | Research |
| Study: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype • Category: Immunology | ||||||
| 05/29/2024 | SANOFI US SERVICES INC. | DUPIXENT (Biological) | — | Cash or cash equivalent | $125.00 | Research |
| Study: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype • Category: Immunology | ||||||
| 04/05/2023 | SANOFI US SERVICES INC. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Immunology | ||||||
| 06/02/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $300.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 04/28/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $1,700.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/31/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $3,350.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/31/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $300.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/17/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $1,650.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/21/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $1,300.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/21/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $1,100.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/21/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $700.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/22/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $4,500.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/03/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $5,400.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/03/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $500.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/07/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $12,600.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/07/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $1,200.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/10/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $4,100.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/05/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $600.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 06/25/2021 | Stryker Corporation | CASCADIA INTERBODY SYSTEM (Device) | Travel and Lodging | Cash or cash equivalent | $180.08 | General |
| Category: SPINE | ||||||
| 06/25/2021 | Stryker Corporation | CASCADIA INTERBODY SYSTEM (Device) | Travel and Lodging | Cash or cash equivalent | $170.74 | General |
| Category: SPINE | ||||||
| 03/29/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $300.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/04/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 01/07/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $1,200.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/16/2020 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $1,600.00 | Research |
| Study: A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) | Regeneron Pharmaceuticals, Inc. | $40,500 | 16 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS | Regeneron Pharmaceuticals, Inc. | $2,900 | 3 |
| A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype | SANOFI US SERVICES INC. | $375.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 99 | 216 | $48,350 | $14,692 |
| 2022 | 3 | 90 | 188 | $45,301 | $13,669 |
| 2021 | 7 | 156 | 221 | $57,845 | $18,031 |
| 2020 | 7 | 159 | 243 | $48,529 | $14,751 |
Total Patients
504
Total Services
868
Medicare Billing
$61,144
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 18 | 116 | $15,138 | $4,857 | 32.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 28 | 28 | $10,248 | $3,083 | 30.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 13 | 13 | $9,074 | $2,842 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 26 | 31 | $8,339 | $2,036 | 24.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 28 | $5,551 | $1,876 | 33.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 23 | 107 | $20,775 | $6,530 | 31.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 41 | 54 | $14,614 | $4,018 | 27.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 26 | 27 | $9,912 | $3,121 | 31.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 32 | 91 | $17,909 | $5,657 | 31.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 43 | 44 | $16,442 | $4,970 | 30.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 29 | 33 | $8,561 | $2,873 | 33.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 16 | 16 | $4,722 | $1,487 | 31.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 12 | 12 | $4,416 | $1,416 | 32.1% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 11 | 11 | $3,777 | $1,138 | 30.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 13 | 14 | $2,018 | $491.81 | 24.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 58 | 136 | $27,206 | $8,616 | 31.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 18 | 18 | $5,332 | $1,706 | 32.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 31 | 32 | $6,908 | $1,529 | 22.1% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 11 | 13 | $4,538 | $1,253 | 27.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 11 | 11 | $1,477 | $650.48 | 44.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 13 | 13 | $1,738 | $568.13 | 32.7% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 17 | 20 | $1,330 | $428.22 | 32.2% |
About Dr. Robert Lowe, M.D
Dr. Robert Lowe, M.D is a Gastroenterology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073590774.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Lowe, M.D has received a total of $44,626 in payments from pharmaceutical and medical device companies, with $375.00 received in 2024. These payments were reported across 24 transactions from 3 companies. The most common payment nature is "" ($43,775).
As a Medicare-enrolled provider, Lowe has provided services to 504 Medicare beneficiaries, totaling 868 services with total Medicare billing of $61,144. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Internal Medicine
- Location Boston, MA
- Active Since 12/23/2005
- Last Updated 12/21/2020
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1073590774
Products in Payments
- DUPIXENT (Biological) $44,275
- CASCADIA INTERBODY SYSTEM (Device) $350.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Boston
Dr. Hiroyuki Aihara, M.d, M.D
Gastroenterology — Payments: $1.0M
Gastroenterology $1.0M
Dr. Ramnik Xavier, Md, MD
Gastroenterology — Payments: $518,235
Gastroenterology $518,235
Adam Cheifetz, M.d, M.D
Gastroenterology — Payments: $435,150
Gastroenterology $435,150
Fredric Gordon, M.d, M.D
Gastroenterology — Payments: $280,379
Gastroenterology $280,379
Dr. Tyler Berzin, Md, MD
Gastroenterology — Payments: $230,903
Gastroenterology $230,903
Dr. Douglas Pleskow, M.d, M.D
Gastroenterology — Payments: $170,196
Gastroenterology $170,196